D. Common combinations

 E. Monitoring therapy  

F. Compliance  

D. Common Combinations

Are chosen from 3 classes of drugs (see attached tables):

         Nucleoside reverse transcriptase inhibitors (NRTIs)

         Non-Nucleoside reverse transcriptase inhibitors (NNRTIs)

         Protease inhibitors (PIs)

Common first and second line combinations are

2 NRTIs + 1PI  

2 NRTIs + NNRTI

 

But watch for drug interaction that increase the risk of toxicity or make the treatment less effective:

Therefore do not use

d4T & ddC                                 causes peripheral neuropathy

d4T & ddI & Hydroxyurea       increased risk of pancreatitis

AZT& d4T                                 effects cancel each other out  
3TC & ddC  
Nevirapine & saquinavir

Always watch other drugs patient may be taking: these may increase or reduce breakdown of HIV drugs by the liver causing treatment failure or toxicity

Especially:     rifampicin and rifabutin

 

 

E. Monitoring therapy

 

3 Monthly:
        
FBC 
        
Biochemistry including amylase, lipids, glucose

        Viral load
         CD4
 

         ? Resistance assay at baseline and if treatment fails

 

 

F. Compliance with treatment

 

HAART will only work if the patient takes it!  

Everyone who takes pills for a long time misses doses (called non-compliance)  

In the USA and Europe patients typically miss about 50% of their prescribed doses of any medication although this may be lower for HAART  

If patients miss <5% of their doses, HAART fails in 20% at 6 months

If patients miss 5-10% of their doses, HAART fails in 55% at 6 months

If patients miss >30% of their doses, HAART fails in 82% at 6 months  

 

The patient should not be told off for being non-compliant – it is just normal human behaviour

How can non-compliance be reduced? Some ideas:

·       Before starting treatment ensure the patient wants to take treatment and understands how to take it and the reasons why doses should not be missed

·       Involve patients in planning a treatment combination that fits into their daily routine

·       Warn patients about common side effects and offer treatment for them if they occur

·       Encourage patients to see the risk of treatment failure (AIDS related illness and death)

·       Show the beneficial effects of regular dosing on their blood tests